Oncology Business Management

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

The FDA has extended the review period for the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib (Zelboraf) for patients with BRAFV600 mutation-positive advanced melanoma by 3 months, making the new decision date November 11, 2015.

Partnership forms to share the latest news about Sarah Cannon's innovative clinical practices and wide-ranging clinical trial programs for cancer.

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer.

At the 2015 ASCO Annual Meeting, the much heralded CancerLinQ big data system for helping oncologists more clearly understand treatment patterns and options was offered for demonstration in advance of its rollout.

Twelve of the nation's leading oncology physicians, researchers and academicians were recognized by their peers as the 2015 Giants of Cancer Care at a ceremony hosted by OncLive at the Chicago Illuminating Company last night. The awardees included medical pioneers selected by a panel of eminent oncologists for landmark achievements in translational research, gene therapy, immuno-oncology and other groundbreaking work that has changed the course of cancer treatment.

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

OncLive proudly announces the 2015 Giants of Cancer Care, a dozen medical pioneers recognized by a panel of eminent oncologists for landmark achievements that have changed the course of cancer treatment. Honorees will be introduced and celebrated at the 3rd Annual Giants of Cancer Care Award Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating Company.

ASCO has proposed a series of payment reforms that it says would significantly increase physician pay and the breadth of patient services available while lowering the overall cost of cancer care.

Oncologists whose research and treatment innovations have changed the course of cancer care will join the elite roster of medical pioneers named OncLive's Giants of Cancer Care when the 2015 honorees are announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

Individuals chosen by this elite committee to receive the 2015 Giants of Cancer Care award for outstanding contributions in the field of oncology will be announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

The FDA's approval in March of the first biosimilar drug for the US market has aroused much concern among physicians.

The healthcare market has been consolidating in recent years with practice mergers, hospital partnerships, and acquisitions or affiliations with primary care and specialist practices.

The first FDA-approved biosimilar, Zarxio, has been blocked from reaching US markets by an injunction from Amgen, the manufacturer of the G-CSF analog counterpart, Neupogen (filgrastim).

The FDA has granted a breakthrough therapy designation to the Bcl-2 inhibitor venetoclax (GDC-0199/ABT-199) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who harbor a 17p deletion (del[17p]).

Earlier diagnosis, longer treatment durations, and increased effectiveness of treatments helped to boost spending on cancer medicines to the $100 billion threshold in 2014, a rise of 10.3% for the year, and up markedly from $75 billion five years earlier.

As the use of testing increases, so does the importance of understanding exactly what it can do for your patients and how to get the most out of the results.